临床宏基因组检测的监管前景

IF 21.3 1区医学 Q1 CLINICAL NEUROLOGY

JAMA neurology Pub Date : 2025-04-07 DOI:10.1001/jamaneurol.2025.0461

Charles Y. Chiu, F. Xavier López-Labrador, Michael R. Wilson, Jutte J. C. de Vries

引用次数: 0

摘要

本观点讨论了监管转变及其对获得创新诊断测试的影响，并提供了解决临床宏基因组测试监管障碍的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Regulatory Landscape for Clinical Metagenomic Testing

This Viewpoint discusses regulatory shifts and their effects on access to innovative diagnostic tests and provides ways to address regulatory barriers for clinical metagenomic testing.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JAMA neurology CLINICAL NEUROLOGY-

CiteScore

41.90

自引率

1.70%

发文量

250

期刊介绍： JAMA Neurology is an international peer-reviewed journal for physicians caring for people with neurologic disorders and those interested in the structure and function of the normal and diseased nervous system. The Archives of Neurology & Psychiatry began publication in 1919 and, in 1959, became 2 separate journals: Archives of Neurology and Archives of General Psychiatry. In 2013, their names changed to JAMA Neurology and JAMA Psychiatry, respectively. JAMA Neurology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.